New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma

Our plain-English summary of New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma, by T. Patel (Journal of Gastroenterology, 2014).

The study

• Author: T. Patel
• Journal: Journal of Gastroenterology
• Published: 2014;49(2):165-72
• Type of article: Review
• Cited by: 48 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Intrahepatic cholangiocarcinoma is an aggressive malignancy and is one of the most devastating cancers of the gastrointestinal tract. The molecular mechanisms contributing to the pathogenesis of these cancers are not well understood. The recognition and distinction of these cancers from other tumors such as perihilar or extrahepatic distal cholangiocarcinoma and hepatocellular carcinoma are important in defining the pathogenesis. New insights into molecular mechanisms contributing to disease pathogenesis are emerging from recent epidemiological, genome-wide profiling and laboratory based studies. These have contributed to an improved understanding of risk factors, genetic mutations and pathophysiological mechanisms that are associated with these tumors. The contribution of well-established risk factors such as biliary tract inflammation and key signaling pathways involved in intrahepatic cholangiocarcinoma are being further defined. These new insights have several important implications for both molecular diagnosis and therapy of these cancers.

In plain English

This article is a review by the author, not an original study. It summarized recent epidemiological, genome-wide profiling and laboratory studies on how intrahepatic cholangiocarcinoma develops. This is a cancer of the small bile ducts inside the liver. Among risk factors, the review described a case-control study by other researchers in which occupational exposure to asbestos appeared to be strongly associated with intrahepatic cholangiocarcinoma, but not with other types of cholangiocarcinoma. The review's text gave no numbers from that study and named no asbestos fiber type; it listed asbestos as possibly a risk factor. It also described cholangiocarcinoma cases among workers at a printing company in Osaka, and the author's earlier meta-analysis, which found an odds ratio of 22.9 for cirrhosis. The rest of the review covered gene mutations, signaling pathways, possible cells of origin and targeted drug therapies. The author noted that many studies mixed different bile duct cancers, that most genetic data were not conclusive, and that therapy studies were small. The author concluded that these insights offered potential for new approaches to detection, diagnosis and therapy.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of recent epidemiological, genomic profiling and laboratory studies; no new data collected
• Who was studied: No study population of its own; the review drew on published epidemiological, genome-wide profiling and laboratory studies of intrahepatic cholangiocarcinoma
• Exposure: Asbestos was one of several risk factors reviewed. Others included cirrhosis, hepatitis B and C, alcohol, and organic solvents in printing work. No asbestos fiber type, product or dose is named
• Main results:
  • In a recent case-control study by other researchers (cited reference 22), occupational exposure to asbestos appeared to be strongly associated with intrahepatic cholangiocarcinoma, but not with other types of cholangiocarcinoma. No figures are given in the text.
  • The review listed asbestos only as possibly a risk factor, alongside some organic solvents
  • A cited report identified several cases of cholangiocarcinoma among workers at a printing company in Osaka. The increased risk was postulated to come from inhaled solvents (1,2-dichloropropane and dichloromethane).
  • The author's earlier meta-analysis of case-control studies (cited reference 30) showed an odds ratio of 22.9 for cirrhosis as a risk factor for intrahepatic cholangiocarcinoma
  • In cited studies of targeted drugs, mostly phase II, single-agent treatment gave median overall survival ranging from 4.4 to 9.8 months
• The authors' conclusion: The author concluded that the new insights improve understanding of how these cancers develop and offer potential for new approaches to detection, diagnosis and therapy
• Limitations the authors state:
  • Many studies did not clearly separate intrahepatic cholangiocarcinoma from other bile duct cancers, limiting the identification of specific risk factors
  • Genetic mutation studies used small numbers of samples and mixed tumor types, so most of the data were not conclusive
  • Most therapy studies were small and included mixed populations of biliary cancers

Topics

Medical terms in this study, explained in our Lexicon: Carcinoma, Inflammation.

Related studies

• Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis — G. Brandi, S. Di Girolamo, et al. (2013)
• Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link — G. Brandi, K. Straif, et al. (2022)
• Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study — F. Vasuri, M. Deserti, et al. (2023)
• Asbestos and Intrahepatic Cholangiocarcinoma — G. Brandi, S. Tavolari (2020)
• Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos — G. Brandi, M. Deserti, et al. (2020)
• Cholangiocarcinoma and Occupational Exposure to Asbestos: Insights From the Italian Pooled Cohort Study — S. Curti, M. Gallo, et al. (2024)

Browse return to medical research.